These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 14673760)

  • 1. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy.
    Ellis RJ; Childers ME; Cherner M; Lazzaretto D; Letendre S; Grant I;
    J Infect Dis; 2003 Dec; 188(12):1820-6. PubMed ID: 14673760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
    Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
    Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men.
    Semple SJ; Patterson TL; Grant I
    Drug Alcohol Depend; 2004 Nov; 76(2):203-12. PubMed ID: 15488344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation.
    Brust D; Polis M; Davey R; Hahn B; Bacharach S; Whatley M; Fauci AS; Carrasquillo JA
    AIDS; 2006 Apr; 20(7):985-93. PubMed ID: 16603850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy.
    Zhang J; Crumpacker CS
    J Infect Dis; 2001 Nov; 184(10):1341-4. PubMed ID: 11679927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.
    Shapiro RL; Ndung'u T; Lockman S; Smeaton LM; Thior I; Wester C; Stevens L; Sebetso G; Gaseitsiwe S; Peter T; Essex M
    J Infect Dis; 2005 Sep; 192(5):713-9. PubMed ID: 16088820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
    Mwamburi DM; Wilson IB; Jacobson DL; Spiegelman D; Gorbach SL; Knox TA; Wanke CA
    Clin Infect Dis; 2005 Jan; 40(1):167-73. PubMed ID: 15614708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
    Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
    J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication.
    Wendel KA; McArthur JC
    Clin Infect Dis; 2003 Oct; 37(8):1107-11. PubMed ID: 14523776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
    Bossolasco S; Calori G; Moretti F; Boschini A; Bertelli D; Mena M; Gerevini S; Bestetti A; Pedale R; Sala S; Sala S; Lazzarin A; Cinque P
    Clin Infect Dis; 2005 Mar; 40(5):738-44. PubMed ID: 15714422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
    Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
    Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non conventional virological markers in HIV-infected patients: T-HIV DNA, 2LTR-HIV DNA and HIV RNA].
    Gariglio R; Taborda MA; Bortolozzi R; McDermott JL; Martini I; Borgognone M; Villanova GV; Varnier OE; Giri AA
    Medicina (B Aires); 2004; 64(5):419-28. PubMed ID: 15560543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.